Lipocine Inc. (NASDAQ:LPCN) – Research analysts at Zacks Investment Research boosted their FY2016 EPS estimates for shares of Lipocine in a research note issued on Monday. Zacks Investment Research analyst J. Vandermosten now anticipates that the brokerage will post earnings per share of ($1.10) for the year, up from their prior estimate of ($1.27). Zacks Investment Research also issued estimates for Lipocine’s Q4 2016 earnings at ($0.22) EPS.

Other research analysts also recently issued reports about the stock. Canaccord Genuity restated a “buy” rating and set a $6.00 target price on shares of Lipocine in a research report on Wednesday, August 10th. HC Wainwright assumed coverage on shares of Lipocine in a research report on Monday, October 17th. They set a “buy” rating and a $25.00 target price on the stock.

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Shares of Lipocine (NASDAQ:LPCN) opened at 3.80 on Wednesday. The firm has a 50-day moving average of $3.82 and a 200-day moving average of $5.00. The firm’s market capitalization is $69.38 million. Lipocine has a 1-year low of $2.51 and a 1-year high of $14.32.

Several hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new stake in shares of Lipocine during the second quarter worth $106,000. Dimensional Fund Advisors LP increased its stake in shares of Lipocine by 1.5% in the second quarter. Dimensional Fund Advisors LP now owns 296,302 shares of the specialty pharmaceutical company’s stock worth $901,000 after buying an additional 4,464 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Lipocine by 14.1% in the second quarter. Vanguard Group Inc. now owns 536,582 shares of the specialty pharmaceutical company’s stock worth $1,631,000 after buying an additional 66,199 shares in the last quarter. BlackRock Investment Management LLC increased its stake in shares of Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 60,169 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Lipocine by 1,117.8% in the second quarter. BlackRock Fund Advisors now owns 433,171 shares of the specialty pharmaceutical company’s stock worth $1,317,000 after buying an additional 397,601 shares in the last quarter. Institutional investors and hedge funds own 46.33% of the company’s stock.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

5 Day Chart for NASDAQ:LPCN

Receive News & Stock Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related stocks with our FREE daily email newsletter.